Error message

The page you requested does not exist. For your convenience, a search was performed using the query about us interactive decision month 2015 05.

Page not found

You are here

Dr. Brian Zikmund-Fisher was selected to receive the 2015 Henry Russel Award. This award, which recognizes both exceptional scholarship and conspicuous ability as a teacher, is one of the highest honors the University bestows upon members of its faculty who are in the early stages of their career. Congrats!

2015 CBSSM Research Colloquium and Bishop Lecture (Lawrence O. Gostin, J.D., LL.D Hon.)

Tue, March 17, 2015, 8:30am to 4:00pm
Location: 
Alumni Center, 200 Fletcher St., Ann Arbor, MI

The Center for Bioethics and Social Sciences in Medicine (CBSSM) Research Colloquium was held Tuesday, March 17, 2015 at the Founders Room, Alumni Center, 200 Fletcher St., Ann Arbor, MI.

The CBSSM Research Colloquium featured the Bishop Lecture in Bioethics as the keynote address.  Lawrence O. Gostin, J.D., LL.D (Hon.) presented the Bishop Lecture with a talk entitled: "Law, Ethics, and Public Health in the Vaccination Debates: Politics of the Measles Outbreak."

Lawrence Gostin is University Professor, Georgetown University’s highest academic rank conferred by the University President. Prof. Gostin directs the O’Neill Institute for National and Global Health Law and is the Founding O’Neill Chair in Global Health Law. He is Professor of Medicine at Georgetown University, Professor of Public Health at the Johns Hopkins University, and Director of the Center for Law & the Public’s Health at Johns Hopkins and Georgetown Universities. Prof. Gostin is also the Director of the World Health Organization Collaborating Center on Public Health Law & Human Rights.

The 2015 Research Colloquium Presentation Schedule:

  • 8:30 AM -- Check in & refreshments
  • 9:00 AM -- Welcome
  • 9:15 AM -- Aaron Scherer, PhD, CBSSM Postdoctoral Fellow: "Elephants, Donkeys, and Medicine: Political Differences in Health Risk Perceptions and Adherence to Medical Recommendations"
  • 9:45 AM -- Natalie Bartnik, MPH, Research Associate, HBHE Genetics Research Group, UM School of Public Health: "Why, how and when oncologists disclose genome sequencing results in clinical practice"
  • 10:15 AM -- Michele Gornick, PhD, MICHR PTSP Postdoctoral Fellow, VA HSRD Fellow & CBSSM Research Investigator: "Information and deliberation make a difference: The public’s preferences for the return of secondary genomic findings"
  • 10:45 AM -- Break
  • 11:00 AM -- Lawrence O. Gostin, JD, LLD (Hon.), 2015 Bishop Lecture in Bioethics: "Law, Ethics, and Public Health in the Vaccination Debates: Politics of the Measles Outbreak"
  • 12:30 PM -- Lunch
  • 1:30 PM -- Stephanie Kukora, MD and Nathan Gollehon, MD, Fellows, Division of Neonatal-Perinatal Medicine, Department of Pediatrics, UM Mott Children’s Hospital: "Epidemiology of outpatient prenatal consultation: implications for decision-making and perinatal outcomes"
  • 2:00 PM -- Minnie Bluhm, PhD, MPH, Assistant Professor, School of Health Sciences, Eastern Michigan University: "Oncologists' decisions about administering late chemotherapy: What makes it so difficult?"
  • 2:30 PM -- Break
  • 2:45 PM -- Danielle Czarnecki, PhD Candidate, UM Department of Sociology: "Moral Women, Immoral Technologies: How Devout Women Negotiate Maternal Desires, Religion, and Assisted Reproductive Technologies"
  • 3:15 PM -- Uchenna Ezeibe, MD, Resident Physician, UMHS Department of Pediatrics & Communicable Diseases: "Pediatric Ethics Consultation Service at a Tertiary Hospital: A Retrospective Review"
Tue, March 10, 2015

Beth Tarini MS, MD shared the findings of her research in a news article on the UMHS website. The research explores parents' perspectives on genomic sequencing for themselves and their children. "Particularly fascinating was that parents’ interest for having predictive genetic testing done for themselves reflected their interest in testing their children too – it appears to be a global decision for the family," Tarini explained. The study will be published in this month's issue of Public Health Genomics.

Research Topics: 

Patients’ Attitudes toward Considering Cost When Making Medical Decisions (Oct-13)

Imagine that for the last three months, you have had a very bad headache – the worst in your life – that won’t go away, even when you take aspirin. In addition to the headache you have also been feeling dizzy. Your doctor tells you that you need to get a brain scan to test whether the headache is being caused by something serious. There are two possible scans you can get: a Magnetic Resonance Imaging (MRI) or a Computerized Axial Tomography (CT) scan.  The MRI provides a slightly more detailed picture and might find something that the CT misses, such as an extremely uncommon blood vessel problem, but nearly all problems serious enough to need treatment would be seen on either the MRI or the CT.

Newmedications offer promise to millions of Americans diagnosed with cancer each year. Yet many of thesenew drugs are expensive; a single medication regimen can cost upwards of $50,000per person per year on top of other medical expenses. Our society is strugglingto find ways to target resources for such technologies. Peter A. Ubel,MD,and colleague Peter J. Neumann, MD (Tufts Medical Center) have been funded by theCalifornia Health Care Foundation to conduct a national survey of oncologistsabout new cancer therapies. Assisting with the project is CBSSM research staffmember Julie Tobi.

What We Do

RESEARCH

Research has been the focus and the strength of the faculty members affiliated with CBSSM. Researchers have pursued groundbreaking investigations topics such as:

  • doctor-patient communication
  • psychological adaptation to disability
  • health care rationing
  • social cognition
  • decision aids to communicate risk
  • informed consent
  • deliberative democracy

EDUCATION

An important mission of CBSSM is to extend the ethics education medical students receive at the University of Michigan. Our current curriculum efforts are focused on enriching the existing curriculum and on making instruction on medical ethics for undergraduate medical students at UM more systematic and focused. Our goal is to increase medical student interest in ethics and their competence in recognizing and resolving ethical issues. Our strategy is to weave ethics into the curriculum throughout the 4 years of training in a way that allows students to build upon what they know of ethical theory and to apply that knowledge to their clinical practice. Additionally, given CBSSM faculty expertise, our aim is to create novel ethics curriculum components that incorporate our empirical work in bioethics and our particular expertise in decision science. 

POLICY/OUTREACH

CBSSM scholars perform the basic and applied scientific research that will improve health care policy and practice, to benefit patients and their families, health care providers, third-party payers, policy makers, and the general public. In our Decision of the Month web feature, we turn a recent research finding into an interactive decision that a patient or a policy maker might face.

PROGRAM IN CLINICAL ETHICS

The Program in Clinical Ethics within CBSSM represents an expansion of existing services designed to promote a culture of patient-centered excellence by developing a comprehensive set of ethics-related activities.  The aims of this program are to: liaise with and provide support to the adult and pediatrics ethics committees; streamline clinical ethics consultation; assist with ethics-related policy development on a regular and proactive basis; organize and administer structured educational programs in clinical ethics; and coordinate empiric research with relevance to clinical ethics within CBSSM.

 

Funded by NIH: National Cancer Institute

Funding Years: 2008-2014

Prostate cancer is a leading cause of cancer death among men, and thousands of men must make treatment decisions every year. Decision making for localized prostate cancer is especially challenging as clinical trials have shown that the standard treatment options of active surveillance, surgery and radiation are comparable in terms of survival. Thus, treatment for prostate cancer is a preference-sensitive decision, with the best choice depending in part on patient attitudes towards the risks and benefits of treatment alternatives. Therefore, ideally the treatment decision will be made with full consideration of patient preferences. As such, it is recommended that patients and their physicians discuss any preferences patients have that might be relevant to the treatment decision. This dialogue is complicated by patients’ lack of experience with sharing in these types of decisions. Additionally, physicians often use medical jargon, making it more difficult for patients to understand their diagnosis and treatment options.  Research is needed to determine the best methods for helping patients communicate their preferences to their physicians so that patient values hold considerable weight in treatment decisions.

The goals of this study are two-fold:

  • To demonstrate to patients some of the issues that might arise during their diagnosis visit that may prevent them from communicating preferences to physicians.
  • To provide solutions that would enable greater patient participation in medical decision making.

PI(s): Angela Fagerlin, PhD and Peter A. Ubel, MD

Co-I(s): John T. Wei, MD; Brian Zikmund-Fisher, PhD; Margaret Holmes-Rovner, PhD; James Tulsky, MD; Stewart Alexander, PhD

Parent grantMichigan Center for Health Communication Research II

Target specific oral anticoagulants (TSOAC)s including dabigatran, rivaroxaban, and apixaban represent novel alternatives to vitamin K antagonists. These medications provide an attractive choice for both physicians and patients alike due to their predictable pharmacokinetics, fixed-dose regimens, lack of routine monitoring, and fewer drug-drug interactions as compared to warfarin. However, these anticoagulants are not without their own unique features and risks, including required dose adjustments for patient specific factors such as renal function, weight, and age, and lack of a routine monitoring parameter to follow patient adherence with therapy. In addition, the cost of TSOACs and the growing number of indications they are currently approved for makes ensuring affordability as well as the correct dosage based on indication for therapy extremely important.

PI(s): Geoffrey Barnes

Co-I(s): Emily Ashjian

Masahito Jimbo, MD, PhD, MPH

Faculty

Masahito Jimbo is Professor of Family Medicine and Urology at the University of Michigan. Having worked as a family physician in both urban (Philadelphia) and rural (North Carolina) underserved areas, he has first-hand knowledge and experience of the challenges faced by clinicians and healthcare institutions to be successful in providing patient care that is personal, comprehensive, efficient and timely. Initially trained in basic laboratory research, having obtained his MD and PhD degrees at Keio University in Tokyo, Japan, Dr.

Last Name: 
Jimbo

PIHCD Working Group: Aaron Scherer, PhD

Thu, May 14, 2015, 3:30pm to 4:30pm
Location: 
B004E NCRC Building 16

Aaron Scherer, PhD

Aaron Scherer will be speaking about a series of studies exploring how beliefs in medical conspiracies influence medical decision making.

 

Pages